20.96
+14.16%
Close of 9 Nov 2026, in HKD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Zai Lab
Its shares trade on HKEX under the ticker 9688.HK. It has been listed since 28 September 2020. In the fiscal year to 31 December 2025, it reported revenue of $460.8m and a net loss of $175.8m. At that date it held total assets of $1.17bn and shareholders' equity of $715.4m.
Zai Lab Ltd. is a biopharmaceutical company. The company is headquartered in Shanghai, Shanghai. The company went IPO on 2020-09-28. The firm is focused on discovering or licensing, developing and commercializing proprietary therapeutics that address areas of large unmet medical need in the China market, including oncology, autoimmune and infectious diseases fields. The firm has a broad pipeline of proprietary drug candidates that range from discovery stage to late-stage clinical programs. These include Niraparib (ZL-2306), ZL-2103, ZL-1101 and others.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 28 Sept 2020
- Employees
- 1,194
- Website
- zailaboratory.com ↗
Leadership
Pay as last reported
- Dr. Du YingChairman of the Board, Chief Executive Officer, Co-Founder$13.8m
- Mr. Joshua SmileyPresident, Chief Operating Officer
- Dr. Yajing ChenChief Financial Officer
- Dr. Rafael AmadoPresident, Head of Global Research and Development
- Mr. F. Ty EdmondsonJoint Company Secretary, Chief Legal Officer
- Ms. Au-yeung NellyJoint Company Secretary
- Dr. John DiekmanLead Independent Director$362,000
- Dr. Richard GaynorIndependent Director$567,000
- Mr. William LisIndependent Director$321,000
- Mr. Scott MorrisonIndependent Director$573,000
- Mr. Leon MoulderIndependent Director$328,000
- Mr. Michel VounatsosIndependent Director$278,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 77
- Environment
- 56
- Social
- 92
- Governance
- 83
- Direct emissions (scope 1)
- 14.55 t
- Energy emissions (scope 2)
- 4,663.84 t
- Value chain emissions (scope 3)
- 65,642 t
- Women in the workforce
- 60%
- Carbon reduction policy
- Yes
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Zai Lab Ltd. focuses on oncology, autoimmune, and infectious diseases in China with a broad pipeline.
- Zai Lab Ltd. has 1,194 full-time employees dedicated to biopharmaceutical development.
- Zai Lab Ltd. commercializes proprietary therapeutics addressing large unmet medical needs in China.
Weaknesses
- Zai Lab Ltd. is headquartered in Shanghai, China, which may limit global expansion.
- Zai Lab Ltd. has a limited number of late-stage clinical programs in its pipeline.
- Zai Lab Ltd. relies on the Chinese market for its primary revenue stream.
Opportunities
- Zai Lab Ltd. can expand its pipeline into new therapeutic areas beyond oncology and autoimmune diseases.
- Zai Lab Ltd. can leverage its IPO in 2020 to secure additional funding for R&D.
- Zai Lab Ltd. can target international markets for its proprietary therapeutics.
Threats
- Zai Lab Ltd. faces competition from other biopharmaceutical companies in China's market.
- Zai Lab Ltd. is subject to regulatory challenges in the Chinese healthcare sector.
- Zai Lab Ltd. depends on the Chinese government's policies for market access.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.